KNOWLEDGE BANK

Interviews

How can bioprinting enable better drug discovery?

CEO, Axolotl Biosciences
Dr Stephanie Willerth is a biomedical engineer entrepreneur and thought leader in D bioprinting and neural tissue engineering As CEO of Axolotl Biosciences and a Full Professor at the University of Victoria she leads innovations in personalized medicine through bioink development and human tissue models Her work bridges academia and industry bringing groundbreaking research into realworld healthca...

Articles

Repurposed Drugs against the Latest Variants of Concerns of SARS-CoV-2

The severe acute respiratory syndrome coronavirus SARSCoV affected all areas of life and the economy by causing COVID and created alarming caution in the form of variants of concerns VoC The latest VoC that are of public health relevance are Alpha B Beta B Gamma P Delta B and Omicron B Due to the emerging spread of these VoCs several vaccines

Research Insights

Analytical Methods For Determination Of Terbinafine Hydrochloride In Pharmaceuticals And Biological Materials

Abstract Terbinafine is a new powerful antifungal agent indicated for both oral and topical treatment of mycosessince It is highly effective in the treatment of determatomycoses The chemical and pharmaceutical analysis of the drug requires effective analytical methods for quality control and pharmacodynamic and pharmacokinetic studies Ever since it was intro

Case Studies

Diagnostics - Stable Aqueous Horseradish Peroxidase

Challenge The main use of Horseradish peroxidise HRP is in diagnostic applications to produce a detectable signal indicating presence of a molecular target Typically HRP is used in conjugates with antibodies the antibody to recognise the molecular target an

Techno Trends

Painless Needle-free Injections - Micro-Jets

Injections will be pain free with MicroJets a novel injector system a needlefree drug delivery system developed by a team of researchers from University of California in collaboration with StratGent Life Sciences This novel needlefree injection would increase patient comfort while eliminating the risk to healthcare workers from needlestick injuries by delivering macro...

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

A BITTER PILL: Exploring the Realm of Drug Counterfeiting

Stephen Ward

Stephen Ward is Pinkerton’s the Vice President of East Coast USA. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.

Angelo Krizmanic

Angelo Krizmanic is Pinkerton’s Vice President of Asia Pacific. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.

2

Changing Paradigms in Use of AI in Chemical Sciences

Prashant S. Kharkar

Prashant S. Kharkar, a well-respected Drug Discovery Researcher with rich industrial experience, received his B. Pharm. degree in 1998. He obtained his PG and Ph.D. (Tech.) degrees Institute of Chemical Technology (ICT), Mumbai, India. Dr. Kharkar completed his postdoctoral research (2006–2009) on neurodegenerative diseases and disorders.

Akash S. Sirsat

Akash Sirsat is pursuing M.Tech in Pharmaceutical Chemistry and Technology at the Institute of Chemical Technology (ICT), Mumbai. He completed his Bachelor of Pharmacy from Sinhgad Institute’s SKNCOP, Pune. His research interests include pharmaceutical chemistry, process development, and applications of AI/ML in pharmaceutical synthesis. He has qualified GPAT, GATE, NIPER, and GAT-B.

3

The Transformative Impact of AI on Regulatory Affairs

Yu Han

Yu Han, DPhil in Engineering Science from the University of Oxford, brings a rich background with experience at manufacturer, global regulatory affairs CRO, and AI sector. Her expertise spans the regulatory landscapes of Asia, the US, and the EU, providing a comprehensive understanding of global pharmaceutical regulations. Passionate about combining AI technology with healthcare, Yu excels in creating innovative engineering tools to advance medical solutions. Her work leverages engineering methodologies to unravel complexities in the medical listing process, streamlining the global product flow.     
 <p>&nbsp;</p>
Email: yu.han@eng.ox.ac.uk

 

4

AI Cures

Anuradha Singh

Anuradha Singh is an Assistant professor at the Department of Chemistry,    S Khanna Girls’ Degree College, University of Allahabad. She is well versed in synthetic chemistry, computer-aided drug design and other techniques used in the field of medicinal chemistry. Dr Singh has published more than 30 research papers/book chapters, in addition to several articles, in journals/books of national and international repute. She has been selected for the prestigious Indian National Science Academy's Visiting Scientist fellowship in 2023. She is a member of several national bodies and referee to various national/ international journals. She successfully led research projects funded by DST and UGC, demonstrating strong leadership and project management skills.

 

5

Neoteric Solvents: A Paradigm Shift in Pharmaceutical Industrial Processes

Abhinab Goswami

Abhinab Goswamiis currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. He has published 01 research paper, 02 review articles and 01 book chapter in renowned journals/international book. His research focus lies in developing the neoteric solvents-based injectable dispersions for intra-auricular administration. He has also identified few neoteric solvents potential for converting them into nanomedicines.

 

Datta Maroti Pawde

Datta Maroti Pawde is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. He has published 05 research papers, 05 review articles and 03 book chapters in renowned journals/international book. Using the dual drug-loaded emulsions at lab-and pilot-scale, the intraarticular injections are developed to treat inflammatory conditions produced at articular or periarticular structures.

 

Syed Nazrin Ruhina Rahman

Syed Nazrin Ruhina Rahman is currently pursuing her Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. She has published 02 research papers, 06 review articles and 04 book chapters in renowned journals/international book. Her research focus lies in managing the dry-eye syndrome by the topical application of cyclosporin A-loaded cationic emulsions.

 

T Raja Sekharan

Faculty Member, SB College of Pharmacy

Tamilvanan Shunmugaperumal

Tamilvanan Shunmugaperumal is currently working at National Institute of Pharmaceutical Education and Research, Guwahati. He has published 58 research papers, 24 review articles and 08 book chapters in renowned journals international book. He is also author of 07 international books and holding 04 granted patents, 03 copyrights materials, etc.. His industrial-oriented research resulted in transfer of cationic emulsion formula from lab to industry.

 

USN Murty

USN Murty is currently working as Director of National Institute of Pharmaceutical Education and Research, Guwahati. He is the man of antimalarial research especially finding molecular leads from plant sources. He holds more than 100 research papers, few review articles and granted patents along with copyrights materials. His articulation in bioinformatics subjects is remarkable and he is the ardent user of artificial intelligence and machine learning in health-related platform.

 

press releasesRead more...

Biomapas Establishes Us Presence With Acquisition of Alira Health’s Cmc Business

Biomapas a leading integrated life sciences services provider today announced its entry into the US market with the acquisition of the Chemistry Manufacturing and Controls CMC business of Alira Health The Bostonbased team which provides integrated

First FDA Breakthrough Therapy designation in PSMA PET imaging granted to Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

Clarity PharmaceuticalsASX CU Clarity or Company a clinicalstage radiopharmaceutical company with a mission to develop nextgeneration products that improve treatment outcomes for patients with cancer is pleased to announce that

Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program

Pfizer Inc NYSE PFE and Blackstone Life Sciences Blackstone today announced a strategic cofunding agreement under which funds managed by Blackstone will pay up to a total of billion of development

Circio and Solid Biosciences enter collaboration to evaluate circVec and POLARIS-101 technology for Genetic Heart Disease

Circio Holding ASA OSE CRNA a biotechnology company developing novel circular RNA expression technology for gene and cell therapy today announces a research collaboration with Solid Biosciences Inc

EirGenix and Merck enter Partnership to Strengthen Global Biologics Development Through Integrated BioReliance® Testing and Regulatory Support

EirGenix Inc and Merck have signed a nonlegally binding memorandum of understanding MOU to support EirGenixs IND and BLA enabling biologics pipeline development The MOU outlines Merck as one of EirGenixs preferred contract testing services vendors providing comprehensive BioReliance services

ProBio Enters Exclusive Global Licensing Agreement with AbTis to Develop Next-Generation ADC Asset

ProBio a global contract research development and manufacturing organization CRDMO today announced that it has entered into an exclusive global licensing agreement with AbTis Co Ltd

EventsRead more...

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

LATEST NEWSRead more...

Immuneering Enters into Collaboration with Astellas to Evaluate Combination Therapies for Pancreatic Cancer

Immuneering has entered into a clinical trial collaboration and supply agreement with Astellas Pharma to evaluate investigational combination therapies for patients with pancreatic cancer

Eppendorf Invests €40 Million in New Manufacturing Facility in Penang, Malaysia

Eppendorf has started construction of a new manufacturing facility at Bandar Cassia Technology Park in Penang Malaysia

Lilly Invests US$3.5 Billion in New Manufacturing Facility for Obesity Medicines in Pennsylvania

Eli Lilly and Company has started construction of a US billion manufacturing facility in Lehigh Valley Pennsylvania as part of its plans to expand medicine production in the United States The new site is one of manufacturing facilities

Natera Enters into Collaboration with Incyte for Phase II Trial in Colorectal Cancer

Natera a precision medicine company has entered into a clinical collaboration with Incyte to support a new Phase II study evaluating an investigational treatment for colorectal cancer CRC

Shionogi Enters into Licence Agreement with Link for Antibiotic Cefiderocol

Shionogi has entered into a licence agreement with Link Healthcare Singapore to develop and commercialise cefiderocol in Singapore and Malaysia

IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours

IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...